Andrew Krumerman, MD Associate Professor of Clinical Medicine Albert Einstein College of Medicine Cardiology, Arrhythmia Service Montefiore Medical Center Bronx, NY
NOTE: This activity was presented as a live visiting faculty grand rounds series beginning on August 20, 2015. Participants who received credit for attending any of the live presentations are not eligible to receive credit for this online release.
Nonvalvular atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in clinical practice and afflicts more than 3 million people in the United States. AF is an independent risk factor for ischemic stroke severity, recurrence, and mortality. Individuals with AF have 4 to 5 times greater risk for ischemic stroke. The National Stroke Association emphasizes the importance of treatment to prevent stroke in patients with AF, noting that patients tend to experience worse outcomes from AF-related stroke compared with non-AF-related stroke. Poor outcomes associated with AF-related stroke include increased mortality, stroke recurrence, functional impairment, and dependency. Quality measures from multiple organizations attest to improvement needed in clinical practice to reduce death from stroke, which includes preventing stroke in patients with AF. Program Developer/Facilitator
. Target Audience
This activity has been designed for cardiologists, hospitalists, internal medicine and primary care physicians, nurse practitioners, physician assistants, nurses, and other clinicians involved in the treatment of patients with AF.
Upon completion of this educational activity, the participant should be able to:
Use evidence-based risk scoring assessments to properly risk stratify patients with AF, considering stroke and bleeding risks.
Discuss key differences in the pharmacologic profiles of the new oral anticoagulants that may impact selection of a specific agent for an individual patient with AF.
Select the correct dosage for oral anticoagulant therapy for patients with AF and renal impairment.
Develop individualized guideline-based antithrombotic treatment regimens for stroke prevention in patients with AF.
Clinical and Patient Educators Association (CPEA) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CPEA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Andrew Krumerman, MD: SentreHEART (Speaker)
Alpesh Amin, MD, MBA, MACP, SFHM: Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, Inc. (speaker); Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, Inc. (Consultant); Bristol-Myers Squibb/Pfizer (Grant/Research); Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, Inc. (Education)
Andrea Funk: Nothing to disclose
Amanda Glazar, PhD: Nothing to disclose
Ashley Marostica, RN, MSN: Nothing to disclose
Gena Dolson: Nothing to disclose
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Clinical and Patient Educators Association (CPEA) and MCM Education do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
ACCME ACCREDITATION STATEMENT: This activity has been planned and implemented in accordance with the requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Clinical and Patient Educators Association and MCM Education. Clinical and Patient Educators Association is accredited by the ACCME to provide continuing medical education for physicians.
This activity is jointly provided by Clinical and Patient Educators Association and MCM Education.
ACCME CREDIT DESIGNATION STATEMENT: Clinical and Patient Educators Association designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in each activity.
CPEA Contact Information
For information about the accreditation of this program, please contact CPEA at 303-953-4580 or email@example.com.
ANCC ACCREDITATION STATEMENT: Global Education Group is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA.
This activity is jointly provided by Global Education Group and MCM Education.
ANCC CREDIT DESIGNATION STATEMENT: This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must view the activity in its entirety and complete the post test and evaluation.
Microsoft Windows 2000 SE or above.
Flash Player Plugin (v126.96.36.199 or greater)
Internet Explorer (v5.5 or greater), or Firefox
Adobe Acrobat Reader*
MAC OS 10.2.8
Flash Player Plugin (v188.8.131.52 or greater)
Adobe Acrobat Reader*
Internet Explorer is not supported on the Macintosh.
*Required to view printable (PDF) version of the lesson. Commercial Support Statements
Funded by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
There is NO fee for this educational activity.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.